Deep Labs conducted the project with the help of Visual Connections, a Windsor Mill, Md.-based firm providing IT and data analytics services to state and federal clients. Together, the companies developed an advanced AI system able to proactively identify potentially fraudulent activity in records from CMS’ Medicare Part D prescription drug benefit program.
The system was a “tremendous success,” able to review millions of records per second and mark any suspicious ones for further investigation, according to Frederick Deese, founder and CEO of Visual Connections. “We are extremely proud to have successfully flagged these potential losses for the CMS, as it strives to cut its waste and overall losses,” added Scott Edington, CEO of Deep Labs.
More articles on AI:
Viewpoint: AI is incompatible with the real-world practice of medicine
Mayo Clinic invests in breast cancer imaging AI
3 lessons NewYork-Presbyterian learned from using AI to reduce length of stay
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
